AOD-9604 in NYC: The Fat-Loss Peptide That Targets Adipose Tissue Without Stimulants

What Is AOD-9604?

AOD-9604 — short for Anti-Obesity Drug 9604 — is a synthetic peptide fragment derived from the C-terminus of human growth hormone (HGH). Specifically, it corresponds to amino acids 176–191 of HGH, the region scientists identified as responsible for the fat-mobilizing effects of growth hormone.

Unlike full growth hormone therapy, AOD-9604 does not significantly raise IGF-1 levels or produce the anabolic effects associated with HGH. This makes it a more targeted option for patients whose primary goal is adipose tissue reduction — without the broader hormonal effects, costs, or regulatory complexity of full HGH therapy.

At Regen Health Physicians NYC, Dr. Ajit Dhaliwal evaluates AOD-9604 as part of comprehensive metabolic and body composition programs for appropriate patients.

How AOD-9604 Works

Growth hormone achieves its lipolytic (fat-burning) effects partly through beta-3 adrenergic receptors on adipocytes (fat cells). AOD-9604 mimics this mechanism selectively:

• Stimulates lipolysis — triggers the breakdown of stored triglycerides in fat cells
• Inhibits lipogenesis — suppresses the creation of new fat deposits
• Does not affect blood glucose or insulin — a key distinction from full HGH
• No IGF-1 elevation — no growth-stimulating effects on bone or tissue

Early-phase clinical trials demonstrated that AOD-9604 reduced body fat in obese subjects without adverse effects on blood glucose, making it distinctly different from stimulant-based fat-loss approaches.

AOD-9604 vs. Stimulant-Based Fat Loss

Most conventional weight-loss aids — including caffeine, ephedrine analogs, and many OTC supplements — work by increasing sympathetic nervous system activity. Side effects include elevated heart rate, anxiety, insomnia, and blood pressure elevation. These risks are compounded in patients with metabolic syndrome, cardiovascular history, or adrenal insufficiency.

AOD-9604 operates through a fundamentally different pathway. Because it targets adipocyte biology rather than the central nervous system, it is generally well-tolerated without cardiovascular stimulation. For patients who cannot tolerate stimulants or who have plateaued on GLP-1 therapies like semaglutide or tirzepatide, AOD-9604 can serve as an adjunct or alternative approach.

Who May Benefit From AOD-9604?

At RHPNY, AOD-9604 is considered for patients who:

• Have struggled to lose stubborn adipose tissue despite dietary discipline and exercise
• Are not candidates for, or are transitioning away from, GLP-1 therapies
• Experience stimulant intolerance or cardiovascular contraindications
• Are optimizing body composition for longevity, not just weight loss
• Want to preserve lean muscle while reducing fat mass

It is typically used as part of a broader metabolic program that may include hormone optimization evaluation, nutritional counseling, and lifestyle modification. AOD-9604 is not a standalone replacement for the foundational elements of body composition.

Typical Protocol

AOD-9604 is commonly administered via subcutaneous injection once daily, typically in the morning before eating, at doses ranging from 300–500 mcg. Treatment periods of 12–24 weeks are common, assessed with periodic body composition measurements (DEXA or BIA).

Safety Profile

To date, AOD-9604 has demonstrated a favorable safety profile in available clinical data. It received GRAS (Generally Recognized as Safe) designation from the FDA for use as a food ingredient, though it is used off-label as a peptide therapy in clinical settings. It is not FDA-approved as a pharmaceutical drug.

Common considerations include:

• Mild injection site reactions: Transient redness or discomfort at the injection site
• Hunger reduction: Some patients report mild appetite suppression
• Well-tolerated: No serious adverse events were observed in clinical trials at therapeutic doses

As with all peptide protocols, comprehensive labs and a full metabolic workup are conducted before initiation at Regen Health Physicians.

Integrating AOD-9604 Into a Comprehensive Metabolic Plan

Body composition is rarely improved by one intervention alone. At RHPNY, peptide protocols are designed alongside a full metabolic picture that includes:

• Fasting insulin, HbA1c, and fasting glucose assessment
• Hormonal evaluation (testosterone, estrogen, cortisol, thyroid)
• Inflammatory markers (CRP, homocysteine)
• Gut health assessment where relevant

When combined with hormone optimization and appropriate lifestyle modifications, patients often see compounding improvements in body composition, energy, and metabolic biomarkers.

If you're curious whether AOD-9604 or another peptide protocol might support your body composition goals, book a consultation with Dr. Dhaliwal at Regen Health Physicians NYC.

---

Medical Disclaimer: AOD-9604 is used off-label in clinical settings and is not FDA-approved as a pharmaceutical drug for weight loss. This article is for educational purposes only. Individual results vary. Consult a qualified physician before beginning any peptide therapy.